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The  I  region  of the  murine  major  histocompatibility  complex  (H-2)  controls  a 
number  of critical  immunologic  functions,  including  genetic  control  of  immune 
responses  (Ir genes) t  (1)  and  immune suppression  (2),  cooperation  between  macro- 
phages and T  cells  (3)  and between T  and B cells  (4),  production of soluble helper 
and suppressor factors (5, 6), and synthesis of cell surface glycoproteins, known as Ia 
antigens, on B cells and subsets ofT cells and macrophages (7). Ia antigens appear to 
be the molecules determining genetic control of immune responsiveness, at  least  in 
part by determining the way in which macrophages "present" antigen to T  cells (3). 
Ir genes were initially defined in experiments using the branched, multichain synthetic 
polypeptide antigens (T,G)-A--L [(tyrosine, glutamic acid)-alanine--lysine] and (H,G)- 
A--L [(histidine,  glutamic acid)-alanine--lysine]  (8).  Mice of the H-2  k haplotype can 
respond to (H,G)-A--L but cannot respond to (T,G)-A--L, whereas mice of the H-2  b 
haplotype  can  respond  to  (T,G)-A--L  but  not  to  (H,G)-A--L  (8).  The  Ir  genes 
controlling immune responsiveness to these antigens map to the/-A subregion (9,  10). 
Anti-Ia antisera and monoclonal antibodies specific for/-region products have been 
useful  in  defining  the  roles of/-region  gene  products  in  in  vitro immune response 
assays, including antigen presentation to T  cells and primary and secondary antibody 
responses  (10-14).  Several reports indicate that these antibodies can modify in vivo 
immune  responses  including  tumor and  graft  rejection,  T  cell  helper  activity and 
granuloma formation (15-22). In this study, we examined the effect of administering 
an anti-I-A  k monoclonal to H-2  k/b heterozygous F1 mice. The data indicate that, in 
certain  experimental  conditions,  an  anti-I-A  k monoclonal  antibody  can  markedly 
suppress  antibody  production  to  (H,G)-A--L while  minimally affecting  (T,G)-A--L 
responses. 
These results suggest that anti-/region  monoclonal antibodies  might be useful  in 
haplotype-specific suppression of humoral responses to antigens under Ir gene control. 
If this type of immunosuppression can be extended  to disease models under Ir gene 
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control,  a  similar approach  using haplotype-specific human  monoclonal  antibodies 
might be applicable to human  autoimmune diseases in which susceptibility is linked 
to HLA-D or DR genotype. This type of immunosuppression offers the great practical 
advantage that the immune response to antigens not under the control of the I  region 
product recognized by the monoclonal antibody would be relatively unaffected. 
Materials  and  Methods 
Mice.  (C3H/DiSn  ×  CWB/13Hz)Fx  mice were  bred  in  our  mouse  colony at  Stanford 
University.  Mice  of  both  sexes  between  the  ages  of  2-10  mo  were  used.  In  individual 
experiments, both control and experimental groups were matched for age and sex. 
Antigen, Immunization Procedures, and Monoclonal Antibody.  (T,G)-A--L 52 and (H,G)-A--L 905 
were  a  gift  from  Dr.  Michael  Sela,  Department  of Clinical Immunology, The  Weizmann 
Institute of Science, Rehovot, Israel. Preparation of these antigens has been described elsewhere 
(23).  For experiments using adjuvant, mice were immunized in the hind footpads with  10 btg 
antigen  emulsified  in  complete  Freund's  adjuvant  (CFA)  containing  2  mg  Mycobacterium 
tuberculosis cells per ml (Difco Laboratories, Detroit, Mich.), followed 3 wk later with the same 
dose of antigen in phosphate-buffered saline (PBS) intraperitoneally. The mice were bled 8 d 
later. Mice receiving antigen in aqueous solution were immunized with 100/~g (T,G)-A--L or 
(H,G)-A--L in PBS i.p., followed 8 d later with the same antigen dosage injected i.p., and were 
bled 8 d after the secondary immunization, as described by Grumet (24). 
The anti-I-A  k monoclonal hybridoma (H 10-3.6) used in these experiments was provided by 
Dr. Patricia Jones,  Dr. Vernon Oi, and Dr. Leonard Herzenberg. This antibody reacts with 
public specificity Ia. 17, which is associated with H-2  k''s'f (25). The hybridoma was maintained 
in ascites form, and the ascitic fluid had a titer >104 in a cell binding assay using H-2  k spleen 
cells as targets. Ascites was injected into the peritoneal cavity of H-2k/bFa  mice according to 
schedules described in Results. 
Antibody Determinations.  The humoral response of F1 mice was determined by a solid-phase 
antigen binding assay similar to the allotyping assay as described by Tsu and Herzenberg (26). 
Briefly, polyvinyl chloride microtiter plates  (Dynatech  Laboratories, Inc., Alexandria, Va.) 
were coated with 30/tl of a solution of (T,G)-A--L or (H,G)-A--L (50 #g/ml in PBS)  for  1 h. 
After removing unbound antigen and washing with PBS containing 5% newborn calf serum, 
20/~1 of a  series of dilutions of mouse serum was added to each well and incubated for  1 h. 
Bound serum antibodies were identified with a 125I-labeled rabbit anti-mouse immunoglobulin 
reagent. After  1 h,  the plates were washed and  the wells cut out  and counted in a  gamma 
counter. All dilutions were tested in duplicate, and the data are expressed as cpm bound by 
each serum dilution. Normal mouse serum (NMS) served as the background control. A  1:10 
dilution of NMS bound between  150 and 300 cpm. 
Results 
As depicted in Figs. 1 and 2, (H,G)-A--L-immunized (C3H ×  CWB)F1 mice treated 
in  vivo with  an  anti-I-A  k monoclonal antibody had  a  significant reduction  in their 
humoral  responses  to  this  antigen.  (C3H  ×  CWB)Fa  mice  immunized  with  (T,G)- 
A--L and given the same monoclonal antibody showed only slight decreases in their 
antibody titers when  compared to the titers of (T,G)-A--L-immunized mice treated 
with  NMS.  The  mice  in  this  experiment  received  two  injections  of  100  /xg  i.p.  of 
aqueous  antigen  on  day  1 and  day 8  and 0.4  to 0.5  ml of monoclonal  antibody or 
NMS on days 0, 2,  7, and 9  (a total of 1.9 ml NMS or H10-3.6 per mouse). 
Use of a  lower dose of the anti-I-A  k monoclonal antibody  (a total of 0.15  ml per 
mouse  given  in  0.01-ml  aliquots  5  times/wk beginning  1 wk before  initial antigen 
injection) had  a  statistically significant  (P <  0.05)  but  much  less dramatic effect on 
the (H,G)-A--L responses without a significant reduction in (T,G)-A--L responsiveness % 
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(data  not  shown).  These  data  demonstrate  that  the  anti-I-A k  monoclonal  antibody 
can  induce  haplotype-specific  suppression  of antibody  response  to  an  antigen  con- 
trolled  by  an Ir gene  in  the I-A subregion  and  that  the  monoclonal  antibody's  effect 
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Interestingly, the specificity of the anti-I-A treatment was lost when the synthetic 
polypeptides were injected in CFA. In addition, the daily monoclonal antibody dosage 
required to induce suppression with CFA immunization, 0.25 ml over a 5-wk period, 
is considerably less  than the dose of monoclonal antibody required for comparable 
effects with an aqueous immunization regimen. 
To test whether the anti-I-A  k monoclonal antibody was effective only when given 
before immunization, mice were given two aqueous injections of (H,G)-A--L intra- 
peritoneally on day  1 and  day 8, bled  15 d  after the first immunization, and  then 
given 1.4 ml of anti-I-A  k ascites or NMS in three injections over the next week. Mice 
treated with  the monoclonal antibody had  a  steady decline in the antigen-binding 
capacity of their sera after day  16, whereas mice treated with  NMS  maintained  a 
relatively constant antibody titer. These data demonstrate that anti-I-A  k monoclonal 
antibody in vivo is capable of suppressing not only primary responses but can also 
suppress established secondary responses. 
Discussion 
This study demonstrates that in vivo administration of a monoclonal antibody that 
recognizes a  specific I-A haplotype in a  heterozygous F1 mouse can exert a  potent, 
relatively specific suppression of a  humoral response controlled by an Ir gene in the 
I-A  subregion. However, specificity of the suppression is not obtained in all circum- 
stances, e.g., when the antigen is administered in CFA. Furthermore, these data show 
that  the  anti-I-A  k  monoclonal  antibody  can  also  partially  suppress  an  ongoing, 
secondary, antibody response. 
Previous work with  antisera against  /-region gene products has established  their 
potential  in  modifying the  immune  system  in  vivo.  Davies  and  Staines  (15),  for 
example,  have shown  prolongation  of allograft  survival  with  alloantisera  directed 
against  the/-region products of the donor. Anti-I-J sera in  rnicroliter quantities  in 
vivo can modulate immune responses to tumors (16,  17) and to schistosomes (18). An 
alloantiserum against I-A  k is capable of reducing T  cell responses to azobenzenearso- 
nate and to a  methylcholanthrene-induced tumor (19,  20).  Perry and her colleagues 
(19)  demonstrated that suppression of footpad swelling in a  mouse heterozygous for 
H-2  determinants  could  be  haplotype  specific  when  the  antigen  is  coupled  to  a 
parental splenocyte. Sprent  (21)  demonstrated that  the same monoclonal antibody 
that we used could block the induction of helper T  cells when given in vivo. Previous 
studies  have not  examined humoral  immune responses or demonstrated  haplotype 
specificity in mice heterozygous for H-2 determinants using an antigen under Ir gene 
control. 
The mechanism underlying the immunosuppression induced by anti-I-A treatment 
is  currently under  investigation.  The  antibody could  potentially exert  a  cytotoxic 
effect on cells expressing I-A, interfere with the function of cells expressing I-A, bind 
or inhibit a  soluble factor(s) with I-A determinants, or stimulate suppressor cells or 
factors. 
Although  the  monoclonal antibody used  is  an  IgG2a  and  is  complement  fixing, 
cytotoxicity is an unlikely mechanism because heterozygous B cells, macrophages, and 
possibly activated T  cells would express both I-A alleles, and then the therapy could 
not  be haplotype specific. Although cytotoxicity could explain  the results observed 
when  CFA  was  used,  this  explanation  again  seems  unlikely because  these  animals ROSENBAUM ET AL.  1699 
suffered no obvious ill effects of the therapy. They appeared vigorous, and the weights 
of lymphoid organs from treated and control animals did not differ (data not shown). 
It is more difficult to decide between the remaining three possibilities: haplotype- 
specific interference of an  I-A-determined cellular function, inhibition of a  soluble 
factor,  or  stimulation  of suppressor  cells.  If  the  first  possibility  is  the  principle 
mechanism of action, the data of Perry and colleagues (19, 20) would suggest that the 
target cell is not solely the B cell because these investigators demonstrate that in vivo 
anti-i-A  alloantisera  reduce T  cell  responses  as  well.  A  likely target  would  be  an 
antigen-presenting macrophage, although the ability of anti-I-A to affect an estab- 
lished immune response might suggest that the mechanism of action does not solely 
involve antigen presentation. 
On  the basis  of these data,  it is difficult to exclude an effect on either a  soluble 
factor(s) or on induction of suppressor cells. This latter possibility has been suggested 
by several investigators (11, 20, 27-29). These studies include the demonstration that 
an anti-DR framework antibody induces suppression in vitro (27), that antibodies to 
immune response gene products induce macrophage suppression ofT cell proliferation 
to myoglobin (11), and  that  anti-I-A in  vivo induces T  cell suppressors of footpad 
swelling after challenge with killed tumor cells (20). Studies to assess the induction of 
suppression in our system are in progress. 
Reconciling  the  specificity  of the  effect  after  aqueous  immunization  with  the 
nonspecificity after CFA  immunization is difficult. This specificity is only relative; 
possibly higher doses of anti-I-A or greater numbers of animals might have revealed 
a statistically significant reduction in response to (T,G)-A--L after aqueous immuni- 
zation. However, unlike the effect seen after immunization with antigen in CFA, the 
effect of anti-I-A  k is relatively much greater for an antigen that is injected in aqueous 
solution  and  is  controlled  by  the  I-A  haplotype  recognized  by  the  monoclonal 
antibody. The conflict is not  due to an artifact of the assay system because results 
with a Farr assay confirm the solid-phase radioimmunoassay results (data not shown). 
Interestingly, other investigators have noted that an anti-Ia reagent can be immuno- 
suppressive under some circumstances even if the antigenic response is not under Ir 
gene control (12, 30) or if the anti-I-A recognizes a nonresponder haplotype in an F1 
heterozygous for Ir genes  (11).  In  Berzofsky and  Richman's  system, using antisera 
against immune response gene products to induce suppression of T  cell proliferation 
(11), the ability to induce suppression depended on the presence of mycobacteria in 
the  adjuvant  used  to  stimulate  T  cells  in  vivo.  Because  antigenic  stimulation  has 
recently been reported to increase expression of I-A on splenic macrophages (31), one 
speculation is that  CFA immunization makes macrophages more susceptible to the 
effects of an anti-I-A antibody. 
The  relative  specificity of anti-I-A  treatment  suggests  that  ultimately  it  might 
provide a useful means of immunotherapy in a variety of human diseases for which 
an immune response gene might be causally related to disease development, and for 
which  immunotherapy  is  currently  used  but  is  limited  by  the  attendant  risks  of 
nonspecificity. Because DR antigens are analogous to Ia antigens  (32)  and because 
disease susceptibility associated with DR antigens is a  dominant  trait with the vast 
majority of individuals with a  given disease heterozygous for the susceptibility gene 
(33),  immunotherapy  with  anti-DR  may  ultimately  prove  feasible.  However, the 
practicality of such therapy depends on toxicity, the availability of haplotype-specific 1700  ANTIBODY  SUPPRESSION OF IMMUNE RESPONSE GENE PRODUCTS 
human anti-DR antibodies, and the role that immune response gene products actually 
play in sustaining a  disease process. The mice appear to tolerate anti-I-A treatment 
well, especially as judged by their ability to make an immune response to an antigen 
not  under  the control  of the haplotype to which  the antisera  is  directed;  however, 
more thorough investigation of toxicity is needed. In doses of up to 2 ml over a  10-d 
period, mice appeared to be vigorous. No evidence of immune complex disease has 
developed as evidenced by studies of renal histology at autopsy. Lower doses of anti- 
I-A did not produce a consistent loss in body weight. In more than  100 mice treated 
with anti-I-A in doses ranging from 0.15-2.0  ml of ascites fluid over a  several week 
period, we observed only two unexpected deaths. In one case, an interstitial pneumonia 
of unknown etiology developed, and in another, autopsy failed to reveal the cause of 
death. Clearly, toxicity is a critical, unanswered question in these studies. 
Although the eventual applicability of these preliminary studies to human disease 
will  require  much more study of both the mechanisms and  the risks involved with 
these antibodies,  our preliminary work suggests that  in  vivo administration  of allo- 
antisera  or  monoclonal  antibodies  to  /-region  products  can  prevent  experimental 
allergic encephalitis in the mouse, susceptibility to which is under control of the MHC 
(Steinman, L., J. Rosenbaum, R. Sriram, and H. McDevitt, in press). 
Summary 
Immune response (Ir) gene products control immunologic function at several critical 
sites. We administered in vivo a  monoclonal antibody reactive with I-A  k to F1 mice 
with  the genotype H-2  u/b. These treated  mice made a  markedly reduced  antibody 
response to antigen  (H,G)-A--L, under the control of I-A  k, but not to antigen  (T,G)- 
A--L, under the control of I-A  b. This relative specificity was lost if the antigen was 
given in complete Freund's adjuvant rather than aqueous solution. The monoclonal 
antibody reduced the antibody titer in an ongoing, secondary response as well. Several 
potential  mechanisms can  be postulated  for this  effect.  This  haplotypic specificity 
might ultimately be relevant to human disease. 
We are indebted to Priscilla  Hendricks, Mark Winters, and Carol Ostrem for expert technical 
assistance. 
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